A position as postdoc is vacant from January 1, 2021 at the Laboratory of Per Svenningsen, Research Unit of Cardiovascular and Renal Research at the Department of Molecular Medicine. The position is for one year with possibility of extension. Job description We are seeking a postdoctoral fellow to work in the field of obesity-induced endothelial dysfunction with focus on examining the role of exosomes for endothelial health Continue reading →

Natoya Haskins Ph.D. 11, Associate Professor, School of Education: After growing up in Williamsburg, Haskins wanted to go a little farther from home for her undergraduate degree. When it came time to get her Ph.D., she knew she wanted to come back to William & Mary for its strong school counseling program. Continue reading →

A multi-disciplinary team led by researchers at the Wyss Institute and MIT created a field-applicable, ultrasensitive diagnostic assay that specifically detects DNA and RNA sequences from all Plasmodium species in symptomatic and asymptomatic malaria, and delivers its results fast in simple reporter devices. Credit: Peter Nguyen / Wyss Institute at Harvard University. Read Time: To achieve the goal of eradicating malaria set by the World Health Organization (WHO)'s Global Malaria Control Programme, it is critical that all local transmission of malaria parasites in defined geographic areas is eliminated. Continue reading →

One of the first randomized controlled trials of its kind has concluded that low-level light therapy is safe in the treatment of moderate traumatic brain injury (TBI). The investigation of 68 patients with moderate TBI showed that light therapy statistically significantly altered multiple diffusion tensor parameters in the late subacute stage. Continue reading →

Salk study: Method to derive blood vessel cells from skin cells suggests ways to slow aging San Diego Community News Group Salk scientists have usedskin cells called fibroblastsfrom young and old patients to successfully create blood vessels cells that retain their molecular markers of age. The teams approach, described in the journaleLifeon Sept. Continue reading →

September 18, 2020 07:05 ET | Source: OncXerna Therapeutics, Inc. OncXernas RNA-based biomarker platform successfully identified responders versus non-responders in trials with late-stage cancer patients Interim results from a Phase 2 trial of bavituximab with KEYTRUDA (pembrolizumab) demonstrates a 19% overall response rate (ORR)and 43% (3/7) ORR from an exploratory analysis in a biomarker-driven subgroup of advanced gastric cancer patients OncXernas RNA-based biomarker panel predicts enhanced response in a Phase 1b trial of navicixizumab in late-stage ovarian cancer patients. Patients in thebiomarker positive panel achieved a 70% ORR, and excludedall who had progressive disease, compared with a 31% ORR for patients in the biomarker negativepanel WALTHAM, Mass., Sept. Continue reading →

Cytokines such as interleukin-2 have long held great promise as cancer treatments, but they can cause nasty side effects that have limited their use. Continue reading →

Back in March, Michigans Covid-19 cases exploded leaping from zero to 3,657 in just two weeks. Detroits three big automakers closed factories temporarily, and the states largest health care system warned it was reaching capacity Continue reading →